Myriad Genetics Inc. announced an international team of cancer researchers has found EndoPredict test accurately predicts which women with ER-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy. Findings from the study were published in the journal, Breast Cancer Research and Treatment.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
